GlassScriptPhysician profile
Emily Kennedy
NPI 1336761352
$11,383.99
in general payments reported to CMS, 2019-2025
44 companies · $2,946 in 2025
The $2,946 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,202 · 2022: $1,878 · 2023: $2,867 · 2024: $2,491 · 2025: $2,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,303 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,303.41 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,321.48 | 2021-2025 | |
| Biogen, INC. | $843.95 | 2021-2025 | Vumerity, Leqembi, Tysabri |
| Neurocrine Biosciences, INC. | $610.48 | 2021-2025 | Ingrezza, Ongentys |
| E.R. Squibb & Sons, L.L.C. | $607.18 | 2022-2025 | Zeposia |
| Tg Therapeutics, INC. | $588.58 | 2023-2025 | |
| Emd Serono, INC. | $573.84 | 2021-2025 | Mavenclad, Mavenclad |
| Ani Pharmaceuticals, INC. | $533.31 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $499.30 | 2021-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $468.22 | 2021-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $443.19 | 2022-2025 | Xcopri |
| Vanda Pharmaceuticals INC. | $350.52 | 2024-2025 | Ponvory |
| Amgen INC. | $324.86 | 2024-2025 | Uplizna |
| Celgene Corporation | $316.18 | 2023-2024 | Zeposia |
| Lundbeck LLC | $278.52 | 2023-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $268.64 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $206.46 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $201.16 | 2023-2024 | Aptiom |
| Biohaven Pharmaceutical Holding Company LTD. | $193.84 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $141.92 | 2021 | |
| Ucb, INC. | $124.98 | 2023-2025 | Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $119.84 | 2022-2023 | Soliris |
| Ipsen Biopharmaceuticals, INC | $119.61 | 2023-2025 | Dysport |
| Argenx US, INC. | $107.55 | 2022-2025 | Vyvgart Hytrulo |
| Genentech, INC. | $106.12 | 2024 | Ocrevus |
| Pfizer INC. | $92.04 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $90.70 | 2024-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $87.20 | 2023-2024 | Rexulti, Nuedexta |
| Impel Pharmaceuticals INC. | $79.97 | 2023 | Trudhesa |
| Octapharma USA, INC. | $78.84 | 2024-2025 | Panzyga |
| Mallinckrodt Hospital Products INC. | $77.45 | 2024-2025 | Acthar |
| Lilly USA, LLC | $76.11 | 2022-2023 | Amyvid |
| Corium, LLC | $73.09 | 2023-2024 | Azstarys, Adlarity |
| Neurelis, INC. | $71.69 | 2023 | Valtoco |
| Axsome Therapeutics, INC. | $69.32 | 2025 | Sunosi |
| Genzyme Corporation | $44.83 | 2023-2025 | |
| Kyowa Kirin, INC. | $44.10 | 2022-2024 | Nourianz |
| Vertex Pharmaceuticals Incorporated | $21.26 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.02 | 2025 | Amvuttra |
| Amneal Pharmaceuticals LLC | $19.93 | 2025 | Brekiya |
| Sunovion Pharmaceuticals INC. | $19.50 | 2022 | |
| Cycle Pharmaceuticals INC | $19.21 | 2025 | Tascenso Odt |
| Eisai INC. | $19.02 | 2023 | |
| Avion Pharmaceuticals | $14.75 | 2023 | Dhivy |
| Kowa Pharmaceuticals America, INC. | $14.23 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.